FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
|Slideshows|June 7, 2018
- Psychiatric Times Vol 36, Issue 5
- Volume 36
- Issue 5
5 Domains of Negative Symptoms of Schizophrenia
Author(s)Dawn I. Velligan, PhD, Larry D. Alphs, PhD
Negative symptoms identified from the Negative Symptom Assessment and the behaviors that might be observed in each of 5 domains.
Advertisement
To view the 2016 article in PDF format, click here.
Articles in this issue
over 7 years ago
Introduction: Meeting Our Personal and Professional Goalsover 7 years ago
Locum Psychiatric Practice: Unexpected, Unheralded Benefitsover 7 years ago
The Role of Social Media in Private Practiceover 7 years ago
Disability: Overview of Concepts Psychiatrists Need to Knowover 7 years ago
Introduction to Immunotherapy of Malignancies for Psychiatristsover 7 years ago
Looking for AmericaAdvertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
What Makes Us Human? The Role of Psychiatry and the Future DSM
3
Reimbursement and Resources: Preparing Clinics for Psilocybin Therapy
4
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
5